# DESCRIPTION

## TECHNICAL FIELD

- define technical field

## BACKGROUND

- introduce viral hemorrhagic fever
- describe Ebola hemorrhagic fever
- describe Marburg hemorrhagic fever
- describe Lassa fever

## SUMMARY

- state technical problem
- introduce berbamine dihydrochloride
- describe structural formula
- provide CAS accession number
- describe use U1
- describe use U2
- describe use U3
- describe use U4
- describe use U5
- specify virus
- specify viral hemorrhagic fever
- describe carrier material
- describe dosage forms
- describe pharmaceutical compound
- describe method for inhibiting virus
- specify virus
- describe method for treating and/or preventing viral hemorrhagic fever
- specify viral hemorrhagic fever
- define pharmaceutically acceptable salt
- specify Ebola virus
- describe inhibition of virus
- describe primed glycoprotein

## DETAILED DESCRIPTION

- introduce embodiments
- specify experimental methods
- describe materials and reagents
- provide background on Ebola virus
- outline pseudovirus technology
- describe cell culture and transfection
- explain luciferase reporter gene detection
- mention limitations of prior art

### Embodiment 1. Verification of Berbamine Dihydrochloride being Capable of Specifically Inhibit the Activity of EBOV by Using a Screening Model for an EBOV Entry Inhibitor

- describe preparation of recombinant virus
- outline transfection and pseudovirus generation
- explain luciferase activity measurement
- describe compound dissolution and mixing
- outline viral inhibition rate evaluation
- introduce tetrandrine as control
- describe specificity analysis using VSVG-expressing pseudovirus
- explain cytotoxicity elimination
- outline experiment replication
- present results

### Embodiment 2: The Antiviral Activity of Berbamine Dihydrochloride Having Nothing to do with its Cytotoxicity

- introduce CCK-8 kit
- describe cell counting and cytotoxicity evaluation
- outline berbamine dihydrochloride treatment
- explain OD value measurement
- present results

### Embodiment 3. Berbamine Dihydrochloride Having a Good Dose-Dependent Inhibition Effect on EBOV

- describe dose-dependent inhibition effect

### Embodiment 4: Berbamine Dihydrochloride Acting on the Entering Stage of a Virus, as Determined by a Drug TOA Experiment

- describe drug TOA experiment
- outline berbamine dihydrochloride treatment
- explain luciferase activity measurement
- present results

### Embodiment 5. Evaluation of Compounds Using Marburg Recombinant Virus and Lassa Recombinant Virus Models

- introduce Marburg and Lassa recombinant virus models
- describe preparation of recombinant viruses
- outline compound evaluation
- present results

### Embodiment 6. Determination of the Capability of Berbamine Dihydrochloride of Binding to the Target Protein GPcl In Vitro by Using a BioLayer Interferometry Technology

- introduce GPcl protein
- motivate BLI technology
- describe biotinylation of GPcl
- outline experiment steps
- detail sensor preparation
- explain data analysis
- present results
- generalize to other viruses
- conclude and scope invention

